Jacobio Pharma: More Thinking on Valuation
Our DCF analysis of Jacobio Pharma results in a US$1.1B pre-money valuation based on the company's lead compounds and the AbbVie license agreement....
372 Views
What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
343 Views
Jacobio Pharma: Focus on Novel Targets
An in-depth overview of the proposed listing of Jacobio Pharmaceuticals using a framework that touches on the science, market opportunity,...
350 Views
Jacobio (加科思药业) Pre-IPO: Right Team but Long Time to Market
Jacobio is a clinical stage China biotech company with a focus on small molecule oncology drugs. The company was founded by Dr. Wang, co-founder of...
449 Views